Evidence map›Paper›PMID 34716678›Full record

ArticleAdvanced healthcare materials2022

Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity.

Shuxiong Chen, Benjamin Evert, Adetayo Adeniyi, Mercè Salla-Martret, Linda H-L Lua, Victoria Ozberk, Manisha Pandey, Michael F Good, Andreas Suhrbier, Peter Halfmann and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Shuxiong ChenCentre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.
Benjamin EvertCentre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.
Adetayo AdeniyiProtein Expression Facility, University of Queensland, Brisbane, QLD, 4072, Australia.
Mercè Salla-MartretProtein Expression Facility, University of Queensland, Brisbane, QLD, 4072, Australia.
Linda H-L LuaProtein Expression Facility, University of Queensland, Brisbane, QLD, 4072, Australia.
Victoria OzberkInstitute for Glycomics, Griffith University, Gold Coast, QLD, 4215, Australia.
Manisha PandeyInstitute for Glycomics, Griffith University, Gold Coast, QLD, 4215, Australia.
Michael F GoodInstitute for Glycomics, Griffith University, Gold Coast, QLD, 4215, Australia.
Andreas SuhrbierQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Peter HalfmannDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53706, USA.
Yoshihiro KawaokaDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53706, USA.
Bernd H A RehmCentre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.ORCID 0000-0003-3908-8903
Griffith University · AUThe University of Queensland · AUUniversity of Wisconsin–Madison · USQIMR Berghofer Medical Research Institute · AU

Funding

ARC Linkage Infrastructure, Equipment and Facilities LE20010014Australian Research Council DP200100874Emergent Ventures at Mercatus Center (George Mason University, USA) Fast Grants Award #2165National Health and Medical Research Council APP1173880Queensland Health, Brisbane QLD02 SARS-CoV-2
6 · The paper itself

Abstract

There is an unmet need for safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are stable and can be cost-effectively produced at large scale. Here, a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS-CoV-2 is used. Coronavirus antigen-coated BPs are described as vaccines against SARS-CoV-2. The spike protein subunit S1 or epitopes from S and M proteins (SM) plus/minus the nucleocapsid protein (N) are selected as antigens to either coat BPs during assembly inside engineered Escherichia coli or BPs are engineered to specifically ligate glycosylated spike protein (S1-ICC) produced by using baculovirus expression in insect cell culture (ICC). BP vaccines are safe and immunogenic in mice. BP vaccines, SM-BP-N and S1-ICC-BP induced protective immunity in the hamster SARS-CoV-2 infection model as shown by reduction of virus titers up to viral clearance in lungs post infection. The BP platform offers the possibility for rapid design and cost-effective large-scale manufacture of ambient temperature stable and globally available vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic.

Indexed as

COVID-19COVID-19 VaccinesAnimalsAntibodies, ViralCricetinaeHumansMicePolymersSARS-CoV-2TemperatureAntibodies, ViralCOVID-19 VaccinesPolymersbiopolyestersCOVID-19SARS-CoV-2self-assemblyvaccines

Identifiers

PMID34716678
PMCPMC8652985
OpenAlexW3210820613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.